Martin David Harp

The IND approval will allow the company to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).

The launch of Blink NutriTears follows a clinical trial that demonstrated improved ocular symptom severity and tear film homeostasis, and that it helped tears stay on the eyes for 33% longer

Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.

Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.

Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.

The UME module adds to the list of ophthalmic diseases available in the dataset.

The company is in the process of seeking regulatory approvals for the lens in the US and Europe.

Abbreviated New Drug Applications seek potential approval of a generic drug product.

The AIOLIS will be used to clinically evaluate patients’ perception of visual disturbances following premium IOL cataract surgery.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with dry eye disease.

Roy Rubinfeld, MD, MA, discussed EpiSmart cross-linking for keratoconus and the ongoing trials and results at the IKA 2024 Symposium.

At the IKA 2024 Symposium, Michael Belin, MD, discussed the ABCD Progression Display he developed to classify disease severity and help diagnose keratoconus earlier.

Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium.

Shelley Cutler, OD, FAAO, gives an overview of how keratoconus diagnosis and treatment over the past 40 years has changed and evolved as well as some key insights from the IKA 2024 Symposium.

William Trattler, MD, talked about his session at the IKA 2024 Symposium that discussed the progression of keratoconus in patients and just how likely it is for them to progress and the importance of following up with these patients.

Kourtney Houser, MD, and Kendall Donaldson, MD, MS, had a session where they talked about the early diagnosis of keratoconus and key indicators in tomography that might help diagnose keratoconus before vision loss.

Recent sessions cast spotlight on emerging technologies and therapies.

Melissa Barnett, OD, Director of Optometry at the University of California, Davis, talked about her session at IKA that focused on keratoconus from the patient perspective.

Elizabeth Yeu, MD, Executive Board Member of IKA, and a cataract and refractive surgeon at Virginia Eye Consultants, talked about perioperative considerations for cataract surgery in keratoconus patients.

Justin Schweitzer, OD, FAAO, from Vance Thompson Vision, talked about his session at the IKA Symposium discussing cross-linking in keratoconus treatment, with a look at both the present and looking toward the future.

Barry Eiden, OD, FAAO, FSLS, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus, the importance of early diagnosis, and the impact this can have on practices.

Christine Sindt, OD, FAAO, Clinical Professor of Ophthalmology and Visual Sciences at the University of Iowa School of Medicine, talked about her session at the meeting focusing on higher order aberrations and the correction of complicated optics on scleral contact lenses.

Alan Glazier, OD, FAAO, talked about a session he is a moderator in that discusses the education of the public on keratoconus, from screening to diagnosis, and the roles clinicians can take to assist in the anxieties of the patients.

Andrew Morgenstern, OD, FAAO, FNAP, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus.

At this year's ARVO meeting, Michael Chaglasian, OD, spoke with Ophthalmology Times about the paper he presented on the detection of glaucoma with a novel widefield imaging device combined with OCT

At this year's ARVO meeting, Irene Santiago Tierno, MS, talked with Ophthalmology Times about the paper she presented on how abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early age-related macular degeneration.

At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in Diabetic macular edema.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.

At this year's ARVO meeting, Edmund Tsui, MD, presented a paper on the analysis of anterior chamber inflammation through automated quantitative assessment of swept-source anterior segment OCT images.

At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.